Trial reportClinical pharmacology in drug development2022
Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects.
Trial report in Clinical pharmacology in drug development, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review.Frontiers in nutrition · 2026Pooled it
- A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults.Clinical and translational science · 2024Trial
- Vaccination timing and humoral suppression with telitacicept in IgA nephropathy.International urology and nephrology · 2026Article
- Clinical Management of Antirheumatic Drug Exposure During Therapeutic Plasma Exchange.Clinical reviews in allergy & immunology · 2026Review
- Twelve-month follow-up after telitacicept withdrawal in patients with SLE: a single-centre study.Lupus science & medicine · 2026Article
- The efficacy and safety of telitacicept and its combination with glucocorticoids in IgA nephropathy: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Case Report: Successful telitacicept treatment for IgA nephropathy with stage 4 chronic kidney disease and acute renal failure.Frontiers in immunology · 2026Article
- Telitacicept for refractory AChR-positive generalized myasthenia gravis: a retrospective real-world study.Frontiers in immunology · 2026Article
- Case Report: Telitacicept in the treatment of systemic lupus erythematosus complicated by acquired hemophilia A.Frontiers in immunology · 2026Article
- Efficacy and safety of telitacicept in IgA nephropathy: a real-world study.Renal failure · 2025Article
- Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights.The American journal of case reports · 2025Article
- Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review.Antibody therapeutics · 2025Review
- Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect.Frontiers in immunology · 2025Article
- Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.Zeitschrift fur Rheumatologie · 2024Article
- The Latest Progress in the Application of Telitacicept in Autoimmune Diseases.Drug design, development and therapy · 2024Review
- Case report: Three cases of systemic lupus erythematosus presenting primarily with massive ascites and significantly elevated CA-125 levels and a review of pseudo-pseudo Meigs' syndrome in literature.Frontiers in immunology · 2024Review
- Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities.Frontiers in pharmacology · 2024Review
- Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies.Frontiers in immunology · 2023Article
- Case Report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies.Frontiers in immunology · 2023Article
- Telitacicept for autoimmune nephropathy.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telitacicept, an injectable recombinant human B-lymphocyte stimulating factor receptor-antibody fusion protein, is a new dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. This study evaluates the pharmacokinetic characteristics, tolerability, and safety of a single subcutaneous injection of various doses (80, 160, and 240 mg) of telitacicept in healthy Chinese subjects. This trial is a single-center, randomized, open-label phase I clinical study that includes three dose groups (80, 160, and 240 mg) with 12 subjects in each dose group. The subjects were randomly assigned to different dose groups in a 1:1:1 ratio for a single subcutaneous administration trial. After a single dose, the maximum serum concentration (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.